ME02224B - Antikancerski fuzioni protein - Google Patents

Antikancerski fuzioni protein

Info

Publication number: ME02224B
Authority: ME; Montenegro
Prior art keywords: antikancerski; protein functions; protein; functions; antikancerski protein
Prior art date: 2010-12-03

Application number

MEP-2015-89A

Other languages

English (en)

Inventor

Jerzy Szczepan Pieczykolan

Krzysztof Kazimierz Lemke

Sebastian Pawlak

Augustin Hittinger

Original Assignee

Adamed Sp Zoo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-03

Filing date

2011-12-05

Publication date

2016-02-20

2010-12-03 Priority claimed from PL393146A external-priority patent/PL393146A1/pl

2011-12-05 Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo

2016-02-20 Publication of ME02224B publication Critical patent/ME02224B/me

Links

102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MEP-2015-89A 2010-12-03 2011-12-05 Antikancerski fuzioni protein ME02224B (me)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
PL393146A PL393146A1 (pl)	2010-12-03	2010-12-03	Przeciwnowotworowe białko fuzyjne
PL39459711		2011-04-18
PCT/EP2011/071719 WO2012072815A1 (en)	2010-12-03	2011-12-05	Anticancer fusion protein
EP11790636.2A EP2646464B1 (en)	2010-12-03	2011-12-05	Anticancer fusion protein

Publications (1)

Publication Number	Publication Date
ME02224B true ME02224B (me)	2016-02-20

Family

ID=45065918

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2015-89A ME02224B (me)	2010-12-03	2011-12-05	Antikancerski fuzioni protein

Country Status (27)

Country	Link
US (1)	US9161991B2 (me)
EP (1)	EP2646464B1 (me)
JP (1)	JP5759557B2 (me)
KR (1)	KR101952460B1 (me)
CN (1)	CN103237808B (me)
AU (1)	AU2011334868B2 (me)
BR (1)	BR112013013548B8 (me)
CA (1)	CA2814595C (me)
CY (1)	CY1116646T1 (me)
DK (1)	DK2646464T3 (me)
EA (1)	EA024452B1 (me)
ES (1)	ES2545895T3 (me)
HR (1)	HRP20150664T1 (me)
HU (1)	HUE027068T2 (me)
IL (1)	IL226207A (me)
ME (1)	ME02224B (me)
MX (1)	MX337436B (me)
NZ (1)	NZ609216A (me)
PH (1)	PH12013500714A1 (me)
PL (1)	PL2646464T3 (me)
PT (1)	PT2646464E (me)
RS (1)	RS54057B1 (me)
SG (2)	SG189370A1 (me)
SI (1)	SI2646464T1 (me)
SM (1)	SMT201500203B (me)
WO (1)	WO2012072815A1 (me)
ZA (1)	ZA201303449B (me)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL219845B1 (pl) *	2011-01-05	2015-07-31	Adamed Spółka Z Ograniczoną Odpowiedzialnością	Przeciwnowotworowe białko fuzyjne
EP2670426B1 (en) *	2011-01-31	2017-05-10	The General Hospital Corporation	Multimodal trail molecules and uses in cellular therapies
WO2014018113A1 (en)	2012-07-24	2014-01-30	The General Hospital Corporation	Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en)	2012-08-30	2014-03-06	The General Hospital Corporation	Compositions and methods for treating cancer
WO2014057436A2 (en)	2012-10-10	2014-04-17	Adamed Sp. Z O.O.	Anticancer conjugate
WO2014141094A1 (en)	2013-03-14	2014-09-18	Adamed Sp. Z O.O.	Anticancer conjugate
US10428132B2 (en)	2015-02-11	2019-10-01	West China Hospital, Sichuan University	Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
CN106632682A (zh) *	2015-08-04	2017-05-10	清华大学	融合蛋白ifn-elp及其应用
AU2020258384B2 (en)	2019-04-15	2026-05-14	Qwixel Therapeutics Llc	Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
JP2023520922A (ja)	2020-04-10	2023-05-22	シートムエックスセラピューティクス，インコーポレイテッド	活性化可能サイトカイン構築物および関連組成物ならびに方法
CA3211924A1 (en)	2021-03-16	2022-09-22	Sayantan Mitra	Masked activatable cytokine constructs and related compositions and methods
KR102839482B1 (ko)	2022-06-09	2025-07-25	제주대학교 산학협력단	Trail을 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR20240068191A (ko)	2022-11-10	2024-05-17	제주대학교 산학협력단	리모닌을 유효성분으로 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR102925278B1 (ko)	2022-11-17	2026-02-09	제주대학교 산학협력단	감귤 무봉 추출물을 유효성분으로 포함하는 탈모증상의 예방 개선 또는 치료용 조성물
CN116143945A (zh) *	2022-12-09	2023-05-23	浙江大学杭州国际科创中心	一种趋化因子与免疫检查点抑制剂融合表达蛋白及其生产方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
KR100510234B1 (ko)	1995-06-29	2005-11-25	임뮤넥스 코포레이션	세포소멸을 유도하는 시토킨
EP1351709B8 (en) *	2000-06-09	2004-12-22	The Government of The United States of America, as represented by The Department of Health and Human Services	Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
EP2272947B1 (en)	2000-09-05	2016-08-10	Biosight Ltd	Peptide conjugated anti-cancer prodrugs
DE10247755B4 (de)	2002-10-14	2006-01-19	Pfizenmaier, Klaus, Prof. Dr.	Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
JP4688678B2 (ja)	2003-11-03	2011-05-25	北京沙東生物技術有限公司	抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用
AU2006279618A1 (en)	2005-08-16	2007-02-22	Genentech, Inc.	Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
US20090131317A1 (en)	2007-06-22	2009-05-21	Affymax, Inc.	Compounds and peptides that bind the trail receptor
ES2657801T3 (es) *	2007-07-10	2018-03-06	Apogenix Ag	Proteínas de fusión de colectina de la superfamilia de TNF
US20090304719A1 (en) *	2007-08-22	2009-12-10	Patrick Daugherty	Activatable binding polypeptides and methods of identification and use thereof
GB0723059D0 (en)	2007-11-23	2008-01-02	Nat Univ Ireland	Improved cytokine design
GB0724532D0 (en)	2007-12-17	2008-01-30	Nat Univ Ireland	Trail variants for treating cancer
US7943733B2 (en)	2007-12-20	2011-05-17	University Of Southern California	Spacers to increase the expression of recombinant fusion proteins
TW200950778A (en)	2008-05-14	2009-12-16	Genentech Inc	Methods of using Apo2L/TRAIL to treat cancer
LT2010012A (lt)	2010-02-10	2011-08-25	Uab Profarma, ,	Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme

2011
- 2011-12-05 CN CN201180057053.1A patent/CN103237808B/zh active Active
- 2011-12-05 RS RS20150407A patent/RS54057B1/sr unknown
- 2011-12-05 SG SG2013027479A patent/SG189370A1/en unknown
- 2011-12-05 HR HRP20150664TT patent/HRP20150664T1/hr unknown
- 2011-12-05 US US13/989,969 patent/US9161991B2/en active Active
- 2011-12-05 PH PH1/2013/500714A patent/PH12013500714A1/en unknown
- 2011-12-05 JP JP2013541381A patent/JP5759557B2/ja active Active
- 2011-12-05 SG SG10201509676UA patent/SG10201509676UA/en unknown
- 2011-12-05 WO PCT/EP2011/071719 patent/WO2012072815A1/en not_active Ceased
- 2011-12-05 CA CA2814595A patent/CA2814595C/en active Active
- 2011-12-05 DK DK11790636.2T patent/DK2646464T3/en active
- 2011-12-05 KR KR1020137017194A patent/KR101952460B1/ko active Active
- 2011-12-05 EA EA201390820A patent/EA024452B1/ru unknown
- 2011-12-05 ME MEP-2015-89A patent/ME02224B/me unknown
- 2011-12-05 ES ES11790636.2T patent/ES2545895T3/es active Active
- 2011-12-05 AU AU2011334868A patent/AU2011334868B2/en active Active
- 2011-12-05 HU HUE11790636A patent/HUE027068T2/en unknown
- 2011-12-05 MX MX2013006213A patent/MX337436B/es active IP Right Grant
- 2011-12-05 NZ NZ609216A patent/NZ609216A/en unknown
- 2011-12-05 BR BR112013013548A patent/BR112013013548B8/pt active IP Right Grant
- 2011-12-05 EP EP11790636.2A patent/EP2646464B1/en active Active
- 2011-12-05 PL PL11790636T patent/PL2646464T3/pl unknown
- 2011-12-05 PT PT117906362T patent/PT2646464E/pt unknown
- 2011-12-05 SI SI201130524T patent/SI2646464T1/sl unknown
2013
- 2013-05-07 IL IL226207A patent/IL226207A/en active IP Right Grant
- 2013-05-13 ZA ZA2013/03449A patent/ZA201303449B/en unknown
2015
- 2015-08-25 SM SM201500203T patent/SMT201500203B/xx unknown
- 2015-08-25 CY CY20151100743T patent/CY1116646T1/el unknown

Also Published As

Publication number	Publication date
ZA201303449B (en)	2014-01-29
ES2545895T3 (es)	2015-09-16
SMT201500203B (it)	2015-10-30
DK2646464T3 (en)	2015-08-24
MX337436B (es)	2016-03-03
US9161991B2 (en)	2015-10-20
AU2011334868A1 (en)	2013-05-02
KR101952460B1 (ko)	2019-02-27
IL226207A0 (en)	2013-07-31
CY1116646T1 (el)	2017-03-15
MX2013006213A (es)	2013-07-29
SG10201509676UA (en)	2015-12-30
CN103237808B (zh)	2016-02-24
HRP20150664T1 (hr)	2015-07-31
EA201390820A1 (ru)	2013-12-30
IL226207A (en)	2016-07-31
HK1186192A1 (en)	2014-03-07
BR112013013548B1 (pt)	2022-03-29
PH12013500714A1 (en)	2013-06-10
PL2646464T3 (pl)	2015-10-30
JP5759557B2 (ja)	2015-08-05
BR112013013548B8 (pt)	2022-11-08
NZ609216A (en)	2014-05-30
CA2814595C (en)	2020-06-16
BR112013013548A2 (pt)	2016-10-11
SI2646464T1 (sl)	2015-07-31
SG189370A1 (en)	2013-05-31
CA2814595A1 (en)	2012-06-07
AU2011334868B2 (en)	2015-01-22
RS54057B1 (sr)	2015-10-30
PT2646464E (pt)	2015-10-05
CN103237808A (zh)	2013-08-07
WO2012072815A1 (en)	2012-06-07
EA024452B1 (ru)	2016-09-30
HUE027068T2 (en)	2016-08-29
EP2646464B1 (en)	2015-06-03
US20130251676A1 (en)	2013-09-26
JP2014502158A (ja)	2014-01-30
EP2646464A1 (en)	2013-10-09
KR20130122764A (ko)	2013-11-08

Publication	Publication Date	Title
HRP20150241T1 (xx)	2015-06-05	Antikancerogeni fuzijski protein
DK2536830T3 (da)	2019-10-21	Polypeptider
IL226307A0 (en)	2013-07-31	Compounds and methods for treating pain
PT2406399T (pt)	2018-03-05	Proteínas mirac
DK3225404T3 (da)	2020-02-10	Fluidpatron
BR112012028556A2 (pt)	2014-04-01	Indóis
DE102011100241A8 (de)	2012-03-01	Nitridhalbleiterbauteil
CR20130111A (es)	2013-05-29	Triazina-oxidiazoles
IL225897B (en)	2019-03-31	Cxcr2 binding polypeptides
PT2641343T (pt)	2020-09-21	Configuração de subtrama
DK2598514T3 (da)	2020-11-16	Proteinoprensning
DE112011104226A5 (de)	2013-09-26	Käfigmutter
DE102011117046A8 (de)	2012-12-27	Doppelkupplungswindungsgetriebe
DE112011101226A5 (de)	2013-01-24	Linearwegmesssystem
DK2539163T3 (da)	2015-09-21	Dækventil
DE102010038420A8 (de)	2013-01-10	Reinigungungsvorrichtung
DK2448659T3 (da)	2013-07-22	Rotorskive
DE102011002623A8 (de)	2012-02-02	Ventilsteuerzeitversteller
DE112011102711A5 (de)	2013-05-29	Hydrostataktor
DK2447426T3 (da)	2013-06-03	Vaske-WC
DE102010035554B8 (de)	2014-12-24	Fußtüröffner
DE102010019119B8 (de)	2013-01-31	Cuttermesser
DE112010005518A5 (de)	2013-04-25	Dichtungsmanchette
IL225495B (en)	2018-07-31	Antimicrobial protein
CO6801789A2 (es)	2013-11-29	N-hetarilmetil pirazolilcarboxamidas